Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253030 · ClinicalTrials.gov registry record
OCT Angiography in Wet AMD
A clinical trial of Neovascular (Wet) Age-related Macular Degeneration (AMD), sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT02253030: Recruiting study of Neovascular (Wet) Age-related Macular Degeneration (AMD), sponsored by Oregon Health and Science University.
NCT02253030 is a study of Neovascular (Wet) Age-related Macular Degeneration (AMD) that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 160 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02253030, a study of Neovascular (Wet) Age-related Macular Degeneration (AMD), is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.
Conditions Studied
Interventions
- DEVICE Optical Coherence Tomography
Study Locations (1)
Oregon
- Casey Eye Institute, Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2014-09 |
| Est. Completion | 2026-12 |
What NCT02253030 shows while recruiting
NCT02253030 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Neovascular (Wet) Age-related Macular Degeneration (AMD) appearing as the primary indexed condition, and to 1 intervention - of which Optical Coherence Tomography is the first listed.
NCT02253030 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02253030 about?
NCT02253030 is a clinical study titled "OCT Angiography in Wet AMD". The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the ...
What is the current status of trial NCT02253030?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2014-09. Estimated completion is 2026-12.
What conditions does trial NCT02253030 study?
This clinical trial studies the following conditions: Neovascular (Wet) Age-related Macular Degeneration (AMD).
What interventions are being tested in trial NCT02253030?
The interventions under investigation include: Optical Coherence Tomography (DEVICE).
Who is sponsoring clinical trial NCT02253030?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02253030 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia